Clinical trial

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

NCT06426511

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-12-01

PhasePHASE2

Study timeline

Study start (actual)2024-12-01Date precision: day

Registry last updated2026-04-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancer, Nonsmall Cellunresolved

Interventions

Toripalimab+ChemotherapyDRUG

Toripalimab+Chemotherapy followed by consolidation toripalimabDRUG

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06426511 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.